The Phase II CONDOR study evaluated a combination of CTLA-4 and PD-L1 inhibitors, tremelimumab and durvalumab, in R/M HNSCC patients with no or low (<25%) PD-L1 expression in the tumor cells. Here, CD274 is linked to neoplasm.